This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
11-13 November 2025
Congress Center BaselBasel, Switzerland

Shalini Andersson, PhD
Vice President of Oligonucleotide Discovery at AstraZeneca
Speaker

Profile

Shalini is Vice President of Nucleic Acid Therapeutics within AstraZeneca’s BioPharmaceuticals R&D, where she leads global strategy and innovation across oligonucleotides, mRNA therapies, gene engineering and targeted delivery platform.

She is highly experienced in drug discovery, development, and strategic leadership, fostering collaborations with external partners and academia. Previously, she led teams in Medicinal Chemistry and Drug Metabolism & Pharmacokinetics for cardiovascular, renal and metabolic therapies. Shalini serves on several scientific boards and advisory groups.

Shalini earned her PhD at the University of Linköping, Sweden, where she also held faculty research and teaching positions prior to transitioning to industry. She has published more than 70 peer-reviewed articles and holds eight patents.

Agenda Sessions

  • Expanding the Druggable Target Space in the Heart with Cardiomyocyte Targeted Oligonucleotides

    13:15